| 000 | 01658 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518093343.0 | ||
| 264 | 0 | _c20201007 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a1534-6080 | ||
| 024 | 7 |
_a10.1097/TP.0000000000002913 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDavis, Scott | |
| 245 | 0 | 0 |
_aTacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. _h[electronic resource] |
| 260 |
_bTransplantation _c04 2020 |
||
| 300 |
_a881-887 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aCalcineurin Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft Rejection _xdiagnosis |
| 650 | 0 | 4 |
_aGraft Survival _xdrug effects |
| 650 | 0 | 4 |
_aHLA Antigens _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aIsoantibodies _xblood |
| 650 | 0 | 4 |
_aKidney Transplantation _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTacrolimus _xadverse effects |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aGralla, Jane | |
| 700 | 1 | _aKlem, Patrick | |
| 700 | 1 | _aStites, Erik | |
| 700 | 1 | _aWiseman, Alexander | |
| 700 | 1 | _aCooper, James E | |
| 773 | 0 |
_tTransplantation _gvol. 104 _gno. 4 _gp. 881-887 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/TP.0000000000002913 _zAvailable from publisher's website |
| 999 |
_c30792671 _d30792671 |
||